OR WAIT null SECS
© 2022 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
April 29, 2022
Now called Camzyos, the therapy is first-in-class and treats the underlying cause of the disease. It is expected to be available next week.
March 22, 2022
The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.
March 21, 2022
But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.
December 13, 2021
Researchers suggest that adjusting the prescribing patterns of about 8% of physicians could result in substantial savings.
November 29, 2021
The study found that nearly half of Americans diagnosed with high blood pressure do not have it sufficiently controlled.
November 26, 2021
Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.
November 12, 2021
Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.
If approved, Jardiance would be the first treatment for adults across the full spectrum of heart failure regardless of ejection fraction.
October 21, 2021
Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.
October 07, 2021
Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group